Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2027
Newsfile Corp•12/11/2026•20:04 ET
0
Key Highlights
- ➤Six-month net loss $3.5M, widening $1.3M year over year
- ➤Cash balance $0.4M at September 30, 2026, up from $0.04M
- ➤Bloom Burton provided $1.2M in non-interest-bearing cash advances
- ➤ATI-1801 FDA feedback defined NDA pathway; approval anticipated as early as Q4 2029
- ➤Long Zone loan repayment extended to November 30, 2026
Expert Statements
Dr. Don Cilla, President and Chief Executive Officer of Appili Therapeutics
“Appili is expanding beyond a traditional infectious disease model to build a National Security Healthcare company focused on dual-use medical technologies that protect military personnel, strengthen national resilience and address important commercial healthcare needs”
Dr. Don Cilla, President and Chief Executive Officer of Appili Therapeutics
“We intend to pursue this strategy with disciplined capital allocation, leveraging partnerships and non-dilutive funding to advance selected programs and create meaningful value for shareholders.”
Building a National Security Healthcare company focused on dual-use medical technologies
Halifax, Nova Scotia--(Newsfile Corp. - November 12, 2026) - Appili Therapeutics Inc. (NEX: APLI.H) (OTC Pink: APLIF) (the "Company" or "Appili"), a biopharmaceutical company building a National Security Healthcare platform focused on dual-use medical technologies, today announced its financial and operational results for the second quarter of its fiscal year 2027, which ended on September 30, 2026. All figures are in Canadian dollars unless otherwise stated.
Get started
Create a free account to read the full story.